Richard Bruton (Dublin Bay North, Fine Gael) | Oireachtas source

-----but the difficulty has been that the technology assessment has shown that at the price being demanded for the drug, it is not medically cost effective. That has been found to be the case not only in Ireland but in Australia, Canada, England and Scotland. All those countries are having difficulty with this company in getting a reasonable pricing of the product. That has been confirmed by the technical work done here.

The Minister is, therefore, taking the lead, as, quite rightly, the Deputy has asked him to do. He is seeking to build a coalition between those bodies in order that each country can work together to try to reach a sensible outcome. The countries in question have not been able to approve it under their reimbursement codes either in light of the high price being charged. They all recognise its benefits but they have not been able to approve it. That is what we need to get from this company.

See this speech in context